China NMPA & US FDA Emergency Approval – Implications to Life Science Companies Relating to COVID-19
On-demandMember: $0.00 Nonmember: $20.00AsiaComplianceDiagnostics/IVDsMedical DevicesOtherPharmaceuticalsQuality Assurance and ControlRegulatory Intelligence/PolicyResearch, Design and Development